Lawrence Higgins
Internal Medicine · New York, NYNPI 1811032006
Payments from drug & device makers
Across 222 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- AstraZeneca$854
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$342
- Viiv Healthcare Company$287
- Amarin Pharma, Inc.$268
- Astellas Pharma US Inc$238
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,95794%
- Education$2466%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 57 | $1,003 |
| AstraZeneca | 45 | $854 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $342 |
| Viiv Healthcare Company | 13 | $287 |
| Amarin Pharma, Inc. | 17 | $268 |
| Astellas Pharma US Inc | 10 | $238 |
| Boehringer Ingelheim | 9 | $214 |
| Lilly USA, LLC | 10 | $163 |
| Eisai Inc. | 6 | $122 |
| Johnson & Johnson | 6 | $120 |
| Amgen(2 entities) | 4 | $104 |
| Novo Nordisk | 6 | $100 |
| Janssen Products, LP | 1 | $100 |
| GSK | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Merck | 2 | $36 |
| EMD Serono, Inc. | 2 | $35 |
| Phadia US Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Metuchen Pharmaceuticals | 1 | $16 |
How this compares
$4,202 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 30 | $117,310 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 27 | $104,110 |
| XifaxanRifaximin | 13 | $52,111 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $35,767 |
| VascepaIcosapent Ethyl | 15 | $12,429 |
| Propranolol Hcl ErPropranolol Hcl | 14 | $985 |
| Rosuvastatin Calcium | 37 | $803 |
| Esomeprazole Magnesium | 14 | $768 |
| Finasteride | 45 | $690 |
| Tamsulosin Hcl | 33 | $689 |
| Bupropion XlBupropion Hcl | 18 | $507 |
| Levocetirizine Dihydrochloride | 17 | $441 |
| Levothyroxine Sodium | 22 | $216 |
| Metformin Hcl | 31 | $178 |
| Atorvastatin Calcium | 24 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq | $287 | $104,11027 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $342 | $52,11113 claims |
| GileadDescovy | $1,003 | $35,76714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.